Free Communications - HPV Testing

8:15 AM • FC 07-01 • International quality assurance of HPV DNA genotyping services: the 2017 global HPV DNA proficiency study > C. Carina Eklund 8:23 AM • FC 07-02 • Clinical validation of the COBAS 6800 HPV test for cervical screening > J. Joakim DILLNER 8:31 AM • FC 07-03 • Clinical validation of the Liferiver Harmonia HPV assay using the VALGENT-4 framework > L. Lan XU 8:39 AM • FC 07-04 • HPV type-specific agreement between linear array HPV genotyping test, ANYPLEX II HPV28 and 21 HPV genoarray within the VALGENT-3 framework > A. Anja Ostrbenk 8:47 AM • FC 07-05 • Performance of the ONCLARITY™, COBAS® and Hybrid CAPTURE II HPV assays on PRESERVCYT® specimens with panel-adjudicated histology > L. Laurence Vaughan 8:55 AM • FC 07-06 • Is co-testing with a 3-type HPV mRNA test a better strategy for women 21-29 years than cytology alone? > B. Bente Falang 9:03 AM • FC 07-08 • Keratin-based sample validity testing improves triage of HPV 16/18/45 positive women using hrHPV E7-oncoprotein testing > I. Isabel Koch 9:11 AM • FC 07-09 • Onclarity performance in HPV DNA detection of formalin fixed paraffin embedded cervical samples > F. Fabio Bottari 9:19 AM • FC 07-10 • HC2® vs COBAS® 4800: comparison of clinical and analytical performances of two clinically validated tests for HPV primary screening of cervical cancer > G. Giampaolo Pompeo 9:27 AM • FC 07-11 • Comparison and benefits of full genotyping of all 14 oncogenic HPV types using INNO-LIPA® EXTRA II versus genotyping HPV-16, HPV-18 individually and pool detection of 12 other high risk HPV with COBAS 4800® among Iranian women > R. Reza Monsef 9:35 AM • FC 07-12 • Buffer and time dependent HPV DNA stability in Colli-Pee® collected FV urine > J. Jade Pattyn